Navigation Links
Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
Date:1/6/2009

EMERYVILLE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore. Under the terms of the agreement, Onyx has obtained option rights to exclusively develop and commercialize SB1518 (designated by Onyx as ONX 0803) and SB1578 (designated by Onyx as ONX 0805) for all potential indications in the United States, Canada, and Europe. S*BIO will retain responsibility for all development costs prior to option exercise, after which Onyx will assume development costs for the U.S., Canada, and Europe subject to S*BIO's option to fund a portion of the development costs in return for enhanced royalties on any future product sales. Upon option exercise for each compound, S*BIO will receive a one-time fee, milestones upon achievement of certain development and sales triggers and royalties on future product sales. Under the terms of the agreement, in December 2008, Onyx made a $25 million payment to S*BIO, including an up-front payment and an equity investment. After recognizing R&D expense related to the S*BIO transaction, Onyx continues to anticipate profitability for the full year 2008 on a non-GAAP basis, excluding stock-based compensation.

"JAK2 is implicated across a broad range of difficult-to-treat illnesses, including cancer and autoimmune diseases, and is one of the most exciting potential new targets in cancer therapy today. These compounds fit with our vision of exploring cutting-edge therapies with broad potential utility," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "This transaction exemplifies our approach of expanding our product portfolio through deals
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Akrimax Pharmaceuticals Announces Manufacturing Partnership
2. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
3. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
4. AUDIO from Medialink and Solvay Pharmaceuticals: New Initiative Urges Women to Address Mens Health this New Year
5. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
6. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
7. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
8. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
9. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
10. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
11. Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... night, which shuts off nighttime production of the hormone ... widely used breast cancer drug, says a new study ... study, "Circadian and Melatonin Disruption by Exposure to Light ... Breast Cancer," published in the journal Cancer Research ... vital to the success of tamoxifen in treating breast ...
(Date:7/24/2014)... Ticket Down is a reliable source for cheap ... Sports Authority Field on July 26th. For the past four years, ... of the best club teams from around the world to North ... about weeks after its completion, fans – new and old alike ... stars in the world compete. Some of these players were already ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Four ... this month of its $3 million renovation of the ... Lokelani presidential/residential three-bedroom suites, just in time to welcome ... , With design direction from the internationally-acclaimed BraytonHughes Design ... largest on the property and the largest in Hawaii—received ...
(Date:7/24/2014)... In a July 9th article in the ... Lotus Blossom Consulting LLC , was quoted in a ... to Cut the High Cost of Infertility . Her advice ... to maximize your chance of success from the first attempt.” ... , “I am always happy to talk with the ...
(Date:7/24/2014)... County, NJ (PRWEB) July 24, 2014 ... a leading specialist in hematology and oncology, Dr. ... Medical Group. Our system welcomes Dr. Upadhyaya to ... physicians comprise CarePoint Health Medical Group, a comprehensive ... County, representing a wide range of specialties. This ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2
... claimed five more victims in Bataan, Rizal and Marikina ... from Valenzuela City and a four-and-a-half child from Balanga, ... administrator of the Amang Rodriguez Medical Center the Valenzuela ... hours after being taken there for treatment Wednesday. ...
... to combat tropical diseases that ails many millions of ... was given a renewed thrust by The Bill & ... more than $68.2 million. ,This fund will ... trypanosomiasis – which are spread by parasites and worms. ...
... Rooney, Coleen McLoughlin launched Children’s Hospice Week in the ... of the work hospices do as well as aid ... has personal experience to speak from. Her eight-year-old sister, ... a regular visitor to Claire House Children’s Hospice in ...
... review that was published in the Friday’s issue of the British ... of fractures in the later years.// ,According to the ... age of 18 years. Hence, it is expected that enhancing bone ... bone loss and osteoporosis. ,The results of 19 studies, ...
... technique to find out if metastasis from the eye cancer ... scientists at Washington University School of Medicine in St. Louis ... of the eye might spread to the liver, where it ... also of the opinion that the molecular screening test might ...
... postmenopausal women with any risk levels of breast cancer. According ... September 1 issue of Clinical Cancer Research//, Raloxifene could protect ... they are at high or low risk of developing the ... drug could reduce the risk in women with a family ...
Cached Medicine News:Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 2Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 3Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 4Health News:Raloxifene Reduces The Risk Of Breast Cancer 2Health News:Raloxifene Reduces The Risk Of Breast Cancer 3
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
(Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... Tests are qualitative enzyme immunoassays (EIA) for ... (IgG or IgM, respectively) in serum. Equivocal ... be supplemented with a standardized western blot ... to support a clinical diagnosis of B. ...
... Thyroid Autoimmunity Test is an enzyme immunoassay ... autoantibodies against human thyroglobulin and human thyroid ... blood and is used as an aid ... thyroid gland disorders are characterized by detection ...
... is dot-blot assay system combining microwell EIA ... purified antigen set at a clinically meaningful ... is detected using the same reagent system ... combines antigens detected in Auto 4 detecting ...
... The ImmunoDOT Autoimmunity Screening Panel 4 ... for screening and detection of autoantibodies ... (SS-A, SS-B, RNP/Sm, and Sm) in ... aid in the diagnosis of systemic ...
Medicine Products: